Free Trial

BeOne Medicines (ONC) Competitors

BeOne Medicines logo
$310.81 +0.78 (+0.25%)
As of 10/24/2025 04:00 PM Eastern

ONC vs. SNY, GSK, ARGX, TAK, INSM, BNTX, TEVA, GMAB, SMMT, and ASND

Should you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

BeOne Medicines vs. Its Competitors

BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$3.81B8.94-$644.79M-$1.73-179.66
Sanofi$44.46B2.85$6.02B$4.1612.41

In the previous week, Sanofi had 14 more articles in the media than BeOne Medicines. MarketBeat recorded 25 mentions for Sanofi and 11 mentions for BeOne Medicines. Sanofi's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.83 indicating that Sanofi is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
13 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BeOne Medicines has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

BeOne Medicines currently has a consensus target price of $345.60, indicating a potential upside of 11.19%. Sanofi has a consensus target price of $62.67, indicating a potential upside of 21.35%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Sanofi
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -3.89%. Sanofi's return on equity of 16.86% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines-3.89% -1.22% -0.72%
Sanofi 21.47%16.86%9.63%

Summary

Sanofi beats BeOne Medicines on 12 of the 16 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONC vs. The Competition

MetricBeOne MedicinesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$34.06B$3.02B$6.24B$10.69B
Dividend YieldN/A57.75%5.72%4.81%
P/E RatioN/A27.9431.4730.88
Price / Sales8.94612.98564.64176.26
Price / CashN/A168.3237.0861.44
Price / Book9.115.6512.056.61
Net Income-$644.79M$33.06M$3.33B$277.10M
7 Day Performance-1.77%3.16%1.93%2.56%
1 Month Performance-5.45%8.14%7.77%3.77%
1 Year PerformanceN/A-2.49%56.40%33.01%

BeOne Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONC
BeOne Medicines
3.0023 of 5 stars
$310.81
+0.3%
$345.60
+11.2%
N/A$34.06B$3.81B0.0011,000Positive News
Analyst Forecast
SNY
Sanofi
4.2703 of 5 stars
$50.62
+1.2%
$62.67
+23.8%
-0.8%$122.82B$44.46B12.1782,878Trending News
Earnings Report
Gap Up
GSK
GSK
1.8588 of 5 stars
$43.92
+0.3%
$37.38
-14.9%
+14.5%$88.97B$40.10B20.3368,629News Coverage
Upcoming Earnings
Dividend Cut
Options Volume
Gap Down
ARGX
argenex
2.6836 of 5 stars
$843.66
+0.8%
$817.53
-3.1%
+48.3%$51.24B$2.25B43.261,599Upcoming Earnings
Analyst Downgrade
TAK
Takeda Pharmaceutical
3.2569 of 5 stars
$14.05
+1.2%
N/A+1.7%$44.17B$30.09B46.8347,455News Coverage
Upcoming Earnings
INSM
Insmed
3.062 of 5 stars
$165.76
+1.6%
$152.88
-7.8%
+122.6%$34.49B$398.11M-29.031,271Upcoming Earnings
Analyst Forecast
BNTX
BioNTech
2.5779 of 5 stars
$105.14
+0.1%
$134.32
+27.8%
-5.4%$25.26B$2.98B-65.716,772News Coverage
Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.633 of 5 stars
$19.33
-1.5%
$25.57
+32.3%
+3.8%$22.51B$16.54B-120.8136,830Analyst Forecast
GMAB
Genmab A/S
3.816 of 5 stars
$33.17
+1.3%
$40.80
+23.0%
+31.0%$21.03B$3.12B16.672,682Analyst Forecast
Short Interest ↑
Analyst Revision
SMMT
Summit Therapeutics
2.796 of 5 stars
$20.99
-4.5%
$31.29
+49.1%
-0.9%$16.32BN/A-20.78110Trending News
Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
ASND
Ascendis Pharma A/S
2.7579 of 5 stars
$210.50
+1.7%
$249.80
+18.7%
+55.6%$12.77B$393.54M-40.791,017Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ONC) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners